Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study

Annals of the Rheumatic Diseases

Volumn 70, Issue 11, 2011, Pages 1905-1913

  Merrill, Joan T ^a   Wallace, Daniel J ^b   Petri, Michelle ^c   Kirou, Kyriakos A ^d   Yao, Yihong ^e   White, Wendy I ^e   Robbie, Gabriel ^e   Levin, Robert ^f   Berney, Seth M ^g   Chindalore, Vishala ^h   Olsen, Nancy ^i,j   Richman, Laura ^e   Le, Chenxiong ^e   Jallal, Bahija ^e   White, Barbara ^e,k  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b Wallace Rheumatic Study Center   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e MEDIMMUNE   (United States)

^f Clinical Research of West Florida Inc   (United States)

^g LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^h Pinnacle Research Group LLC   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^k UCB PHARMA   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIMALARIAL AGENT; BICARBONATE; CORTICOSTEROID; GLUCOSE; HEMOGLOBIN; INTERFERON; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PREDNISONE; PROTEIN; SIFALIMUMAB;

ADULT; ANAPHYLAXIS; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BICARBONATE BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DIARRHEA; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIVERTICULITIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; GENITAL HERPES; GLUCOSE BLOOD LEVEL; HIP DISLOCATION; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX DISEASE; IMMUNOGENICITY; ISCHIALGIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MENORRHAGIA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREND STUDY; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS REACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INTERFERON TYPE I; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053562466     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.144485     Document Type: Article

References (54)

1. Hochberg MC, Petri M. Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 1993;5:575-86. (Pubitemid 23290056)
2. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999;42:1785-96.
3. Dobkin PL, Da Costa D, Dritsa M, et al. Quality of life in systemic lupus erythematosus patients during more and less active disease states: differential contributors to mental and physical health. Arthritis Care Res 1999;12:401-10.
4. Petri M. Monitoring systemic lupus erythematosus in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:687-97. (Pubitemid 47163598)
5. Von Feldt JM. Systemic lupus erythematosus. Recognizing its various presentations. Postgrad Med 1995;97:79, 83, 86 passim.
6. Da Costa D, Dritsa M, Bernatsky S, et al. Dimensions of fatigue in systemic lupus erythematosus: relationship to disease status and behavioral and psychosocial factors. J Rheumatol 2006;33:1282-8. (Pubitemid 44025141)
7. Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 2004;43:1580-6. (Pubitemid 39642587)
8. Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93-6. (Pubitemid 32410092)
9. Clarke AE, Esdaile JM, Bloch DA, et al. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993;36:1548-59. (Pubitemid 23327753)
10. Ginzler EM, Aranow C. Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Baillieres Clin Rheumatol 1998;12:495-510. (Pubitemid 28488245)
11. Cunnane G, Lane NE. Steroid-induced osteoporosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:311-29, vi-vii. (Pubitemid 30198761)
12. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006;18:676-82. (Pubitemid 44635182)
13. Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 2007;316:359-86.
14. Niewold TB, Hua J, Lehman TJ, et al. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492-502. (Pubitemid 47365615)
15. Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006;38:550-5.
16. Demirci FY, Manzi S, Ramsey-Goldman R, et al. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann Hum Genet 2007;71:308-11. (Pubitemid 46585673)
17. Criswell LA. The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis 2008;66:176-83.
18. Sigurdsson S, Göring HH, Kristjansdottir G, et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008;17:872-81. (Pubitemid 351368993)
19. Kariuki SN, Kirou KA, MacDermott EJ, et al. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009;182:34-8.
20. Niewold TB, Kelly JA, Flesch MH, et al. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008;58:2481-7.
21. Salloum R, Franek BS, Kariuki SN, et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum 2010;62:553-61.
22. Vallin H, Perers A, Alm GV, et al. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999;163:6306-13.
23. Lövgren T, Eloranta ML, Båve U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004;50:1861-72. (Pubitemid 38725099)
24. Lövgren T, Eloranta ML, Kastner B, et al. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006;54:1917-27. (Pubitemid 43877941)
25. Baccala R, Hoebe K, Kono DH, et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13:543-51. (Pubitemid 46828489)
26. Santer DM, Yoshio T, Minota S, et al. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol 2009;182:1192-201.
27. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.
28. Cederblad B, Blomberg S, Vallin H, et al. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells. J Autoimmun 1998;11:465-70. (Pubitemid 28520202)
29. Blomberg S, Eloranta ML, Cederblad B, et al. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001;10:484-90. (Pubitemid 32675048)
30. Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001;159:237-43. (Pubitemid 33704208)
31. Wenzel J, Uerlich M, Wörrenkämper E, et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 2005;153:1011-15. (Pubitemid 41540770)
32. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71. (Pubitemid 32011791)
33. Dall'era MC, Cardarelli PM, Preston BT, et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692-7. (Pubitemid 41667141)
34. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-15. (Pubitemid 36297546)
35. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23. (Pubitemid 36350866)
36. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003;36:481-90. (Pubitemid 37498244)
37. Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67. (Pubitemid 39643944)
38. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62. (Pubitemid 44497776)
39. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009;18:980-9.
40. Morris LF, Lemak NA, Arnett FC Jr, et al. Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J 1996;89:810-14. (Pubitemid 26286686)
41. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005;24:178-81. (Pubitemid 40552976)
42. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43:1431-42. (Pubitemid 30452458)
43. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
44. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
45. National Cancer Institute. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0. 2006. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf (accessed 28 March 2011) .
46. Maintenance and Support Services Organization. Medical Dictionary for Regulatory Activities. http://www.meddramsso.com/ (accessed 28 March 2011).
47. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009;pii:374312.
48. Yao Y, Richman L, Morehouse C, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS ONE 2008;3:e2737.
49. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8. (Pubitemid 41785892)
50. Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003;42:1372-9. (Pubitemid 37407029)
51. Ramsey-Goldman R, Isenberg DA. Systemic lupus erythematosus measures. Arthritis Rheum 2003;49:S225-33.
52. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-3. (Pubitemid 19246303)
53. Gladman DD, Urowitz MB, Kagal A, et al. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000;27:377-9. (Pubitemid 30095467)
54. Bissonnette R, Papp K, Maari C, et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol 2010;62:427-36.